$VIR
Vir Biotechnology, Inc. Stock $vir

$vir Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000162828023036702 Filed on November 03, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$16.79M	$2.639M
YoY Change	-66.03%	-99.3%
Cost Of Revenue	$798.0K	$38.00K
YoY Change	-86.69%	-99.83%
Gross Profit	$15.99M	$2.601M
YoY Change	-63.17%	-99.26%
Gross Profit Margin	95.25%	98.56%
Selling, General & Admin	$43.09M	$41.08M
YoY Change	11.22%	-4.85%
% of Gross Profit	269.5%	1579.39%
Research & Development	$111.9M	$148.3M
YoY Change	-27.88%	29.86%
% of Gross Profit	699.95%	5699.85%
Depreciation & Amortization	$4.451M	$4.500M
YoY Change	127.91%	181.25%
% of Gross Profit	27.84%	173.01%
Operating Expenses	$155.0M	$189.3M
YoY Change	-20.07%	20.33%
Operating Profit	-$139.0M	-$186.7M
YoY Change	-7.63%	-195.78%
Interest Expense	$19.74M	$19.20M
YoY Change	-21.18%	-550.92%
% of Operating Profit
Other Income/Expense, Net	-$1.485M	$20.11M
YoY Change	-94.33%	-11.69%
Pretax Income	-$120.8M	-$166.6M
YoY Change	-20.36%	-176.53%
Income Tax	-$4.784M	-$3.213M
% Of Pretax Income
Net Earnings	-$116.0M	-$163.4M
YoY Change	14.14%	-193.21%
Net Earnings / Revenue	-690.85%	-6192.23%
Basic Earnings Per Share		-$1.22
Diluted Earnings Per Share	-$0.86	-$1.22
COMMON SHARES
Basic Shares Outstanding	134.5M shares	134.3M shares
Diluted Shares Outstanding		134.3M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.522B	$1.697B
YoY Change	-36.62%	-27.7%
Cash & Equivalents	$241.6M	$452.1M
Short-Term Investments	$1.281B	$1.245B
Other Short-Term Assets	$7.600M	$4.800M
YoY Change	-71.21%	-92.85%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$1.588B	$1.769B
YoY Change	-36.95%	-26.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$96.02M	$99.31M
YoY Change	-9.08%	-0.91%
Goodwill	$16.90M	$16.94M
YoY Change	0.0%	0.0%
Intangibles	$22.57M	$25.46M
YoY Change	-31.11%	-22.59%
Long-Term Investments	$105.3M	$39.60M
YoY Change	339.98%	16.12%
Other Assets	$18.86M	$21.80M
YoY Change	-11.16%	61.66%
Total Long-Term Assets	$330.8M	$275.7M
YoY Change	16.9%	-2.35%
TOTAL ASSETS
Total Short-Term Assets	$1.588B	$1.769B
Total Long-Term Assets	$330.8M	$275.7M
Total Assets	$1.919B	$2.045B
YoY Change	-31.51%	-24.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.334M	$3.627M
YoY Change	-1.37%	33.25%
Accrued Expenses	$104.2M	$146.1M
YoY Change	-78.69%	-48.3%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$175.4M	$165.1M
YoY Change	-65.68%	-46.45%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$14.26M	$13.13M
YoY Change	81.35%	83.28%
Total Long-Term Liabilities	$14.26M	$13.13M
YoY Change	81.35%	83.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$175.4M	$165.1M
Total Long-Term Liabilities	$14.26M	$13.13M
Total Liabilities	$328.8M	$369.8M
YoY Change	-54.59%	-32.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$237.8M	-$121.9M
YoY Change	-163.04%	-125.45%
Common Stock	$13.00K	$13.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.590B	$1.675B
YoY Change
Total Liabilities & Shareholders Equity	$1.919B	$2.045B
YoY Change	-31.51%	-24.15%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$116.0M	-$163.4M
YoY Change	14.14%	-193.21%
Depreciation, Depletion And Amortization	$4.451M	$4.500M
YoY Change	127.91%	181.25%
Cash From Operating Activities	-$107.9M	-$155.9M
YoY Change	-407.14%	-232.23%
INVESTING ACTIVITIES
Capital Expenditures	$1.573M	$3.700M
YoY Change	-87.51%	-119.48%
Acquisitions
YoY Change
Other Investing Activities	-$103.3M	-$55.20M
YoY Change	-26.5%	-91.42%
Cash From Investing Activities	-$104.8M	-$59.00M
YoY Change	-31.58%	-91.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.680M	300.0K
YoY Change	-16.46%	-84.89%
NET CHANGE
Cash From Operating Activities	-107.9M	-155.9M
Cash From Investing Activities	-104.8M	-59.00M
Cash From Financing Activities	1.680M	300.0K
Net Change In Cash	-211.0M	-214.6M
YoY Change	81.88%	-60.46%
FREE CASH FLOW
Cash From Operating Activities	-$107.9M	-$155.9M
Capital Expenditures	$1.573M	$3.700M
Free Cash Flow	-$109.5M	-$159.6M
YoY Change	-585.83%	-216.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	29649000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	99309000	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4500000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14600000	usd
CY2022Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1600000	usd
CY2022Q4	vir	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	48880000	usd
CY2022Q4	vir	Payroll And Related Expenses Current PayrollAndRelatedExpensesCurrent	28286000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	15228000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4137000	usd
CY2022Q4	vir	Excess Funds Payable Under Grant Agreements Current ExcessFundsPayableUnderGrantAgreementsCurrent	7652000	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4336000	usd
CY2023Q3	vir	Number Of Directors On Brii Bio Parents Board NumberOfDirectorsOnBriiBioParentsBoard	1	director
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.106
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.108
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.996
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.015
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.038
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.112
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.030
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.036
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.034
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.044
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.036
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-499088000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	617440000	usd
	vir	Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting	0	shares
	vir	Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting	55080	shares
	vir	Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan	0	shares
	vir	Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan	7176	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133969878	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134711777	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.58
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15102516	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11438772	shares
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-507437000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	905918000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8293000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	288478000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.016
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.318
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Revenues Revenues	2639000	usd
CY2022Q3	us-gaap	Revenues Revenues	374557000	usd
	us-gaap	Revenues Revenues	69393000	usd
	us-gaap	Revenues Revenues	1566387000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	38000	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	22253000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1967000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	140323000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	148253000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	114166000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	477756000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41080000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	43174000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	983570000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-20896000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-120019000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	66254000	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	11920000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7506000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	30447000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	37852000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77652000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-507437000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	905918000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8293000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	288478000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-163413000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	175312000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-499144000	usd
	us-gaap	Net Income Loss NetIncomeLoss	617440000	usd
CY2023Q3	vir	Net Income Loss Net Of Tax Attributable To Noncontrolling Interest NetIncomeLossNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2022Q3	vir	Net Income Loss Net Of Tax Attributable To Noncontrolling Interest NetIncomeLossNetOfTaxAttributableToNoncontrollingInterest	0	usd
	vir	Net Income Loss Net Of Tax Attributable To Noncontrolling Interest NetIncomeLossNetOfTaxAttributableToNoncontrollingInterest	-56000	usd
	vir	Net Income Loss Net Of Tax Attributable To Noncontrolling Interest NetIncomeLossNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-163413000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	175312000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-499088000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	617440000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.58
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133969878	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134711777	shares
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-163413000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	175312000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-499144000	usd
	us-gaap	Net Income Loss NetIncomeLoss	617440000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7194000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1003000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4327000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7222000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10781000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	606659000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-56000	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-491866000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	606659000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1810208000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26944000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1003000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-163413000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1675085000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1952012000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2044000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24814000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4327000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	175312000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2149855000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2077963000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3395000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2605000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	83044000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7222000	usd
	vir	Contributions From Noncontrolling Interest Owners ContributionsFromNoncontrollingInterestOwners	100000	usd
	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	100000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-499144000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1675085000	usd
	vir	Stock Issued During Period Value Grant Agreement StockIssuedDuringPeriodValueGrantAgreement	28462000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3602000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2066000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	77217000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-10781000	usd
	us-gaap	Net Income Loss NetIncomeLoss	617440000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2149855000	usd
	us-gaap	Profit Loss ProfitLoss	-499144000	usd
	vir	Change In Estimated Constraint On Profit Sharing Amount ChangeInEstimatedConstraintOnProfitSharingAmount	-28101000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14573000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	399000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	399000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1315000	usd
	vir	Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue	0	usd
	vir	Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue	-93803000	usd
	vir	Noncash Lease Expense NoncashLeaseExpense	6218000	usd
	vir	Noncash Lease Expense NoncashLeaseExpense	6473000	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	20895000	usd
	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	120019000	usd
	vir	Change In Estimated Fair Value Of Contingent Consideration ChangeInEstimatedFairValueOfContingentConsideration	-637000	usd
	vir	Change In Estimated Fair Value Of Contingent Consideration ChangeInEstimatedFairValueOfContingentConsideration	7890000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	83044000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	77217000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	6899000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	7474000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	301000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-491872000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11023000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3434000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2003000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	65144000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2547000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-24506000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1628127000	usd
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	22000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	55432000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	1069752000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	84836000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	269440000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	183000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3602000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2066000	usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	usd
	vir	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	usd
	vir	Payment Of Contingent Consideration PaymentOfContingentConsideration	1197000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5800000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32750000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-395618000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	620551000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	983966000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	7057000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	472350000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	983966000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	1700000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></div>
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q3	us-gaap	Other Assets Current OtherAssetsCurrent	4800000	usd
CY2023Q3	vir	Financial Assets Amortized Cost Basis FinancialAssetsAmortizedCostBasis	1711677000	usd
CY2023Q3	vir	Financial Assets Gross Unrealized Holding Gains FinancialAssetsGrossUnrealizedHoldingGains	29000	usd
CY2023Q3	vir	Financial Assets Gross Unrealized Holding Losses FinancialAssetsGrossUnrealizedHoldingLosses	1229000	usd
CY2023Q3	vir	Financial Assets Fair Value FinancialAssetsFairValue	1721302000	usd
CY2022Q4	vir	Financial Assets Amortized Cost Basis FinancialAssetsAmortizedCostBasis	2403183000	usd
CY2022Q4	vir	Financial Assets Gross Unrealized Holding Gains FinancialAssetsGrossUnrealizedHoldingGains	0	usd
CY2022Q4	vir	Financial Assets Gross Unrealized Holding Losses FinancialAssetsGrossUnrealizedHoldingLosses	8396000	usd
CY2022Q4	vir	Financial Assets Fair Value FinancialAssetsFairValue	2426679000	usd
	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	0	usd
	us-gaap	Financing Receivable Accrued Interest Writeoff FinancingReceivableAccruedInterestWriteoff	0	usd
	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-1200000	usd
CY2022	us-gaap	Debt Securities Available For Sale Unrealized Gain Loss DebtSecuritiesAvailableForSaleUnrealizedGainLoss	-8400000	usd
CY2020	vir	Number Of Programs The Collaboration Is To Focus On NumberOfProgramsTheCollaborationIsToFocusOn	3	program
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	128958000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	126352000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	20743000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	105609000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4400000	usd
CY2023Q3	vir	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	65693000	usd
CY2023Q3	vir	Payroll And Related Expenses Current PayrollAndRelatedExpensesCurrent	27176000	usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	15415000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	13557000	usd
CY2023Q3	vir	Excess Funds Payable Under Grant Agreements Current ExcessFundsPayableUnderGrantAgreementsCurrent	9217000	usd
CY2023Q3	vir	Profit Share Amount Constraint ProfitShareAmountConstraint	6964000	usd
CY2022Q4	vir	Profit Share Amount Constraint ProfitShareAmountConstraint	357762000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3987000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3711000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12711000	usd
CY2023Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	42000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	10447000	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	146111000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	489090000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.999
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.009
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.040
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.044
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26944000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24814000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	83044000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	77217000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-163413000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	175312000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134289620	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132729530	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	133969878	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132422028	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2144302	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2227493	shares
CY2023Q3	vir	Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting	0	shares
CY2022Q3	vir	Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting	75759	shares
CY2023Q3	vir	Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan	0	shares
CY2022Q3	vir	Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan	13726	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134289620	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134963317	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.32
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.30
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15731354	shares
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10575325	shares
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-166626000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	217732000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3213000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42420000	usd
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.019
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.195
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	12900000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	10600000	usd
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
vir-20230930_def.xml	Edgar Link	unprocessable
vir-20230930_cal.xml	Edgar Link	unprocessable
0001628280-23-036702-index-headers.html	Edgar Link	pending
0001628280-23-036702-index.html	Edgar Link	pending
0001628280-23-036702.txt	Edgar Link	pending
0001628280-23-036702-xbrl.zip	Edgar Link	pending
a20231103-q310qex101.htm	Edgar Link	pending
a20231103-q310qex102.htm	Edgar Link	pending
a20231103-q310qex103.htm	Edgar Link	pending
a20231103-q310qex311.htm	Edgar Link	pending
a20231103-q310qex312.htm	Edgar Link	pending
a20231103-q310qex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vir-20230930.htm	Edgar Link	pending
vir-20230930.xsd	Edgar Link	pending
vir-20230930_lab.xml	Edgar Link	unprocessable
vir-20230930_pre.xml	Edgar Link	unprocessable
vir-20230930_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VIR
Vir Biotechnology, Inc. Stock $vir

2023 Q4 Form 10-Q Financial Statement

#000162828023036702 Filed on November 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VIR Vir Biotechnology, Inc. Stock $vir

2023 Q4 Form 10-Q Financial Statement

#000162828023036702 Filed on November 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VIR
Vir Biotechnology, Inc. Stock $vir